An in vitro investigation of the structure-activity profiles for a range of 9-anilinoacridines on drug-resistant Plasmodium falciparum is reported. C-3, 6-diamino substitution, low lipophilicity, and high pKa values substantially increased the activities of the 9-anilinoacridines tested. There appeared to be no correlation between DNA binding and antimalarial activity. 3,6-LDiamino-1'-amino-9-anilinoacridine (compound 13) was the most active compound tested; it had a 50%N inhibitory concentration of 25 nM. In vitro mammalian cell growth assays showed compound 13 to be one of the least cytotoxic 9-anilinoacridines (50%Y inhibitory concentration, 15 PM). Both compound 13 and the antimalarial drug pyronaridine inhibited the decatenation activity of P. falciparum DNA topoisomerase II at concentrations of 10 and 11 PM, respectively.
The incidence of drug resistance in patients with Plasmodium falciparum malaria is continuing to increase in large areas of the world and is a substantial public health problem (14) . This issue has prompted the active and rational development of alternative drugs that may be effective against such drug-resistant strains.
Recently, we reported that several 1'-substituted 9-anilinoacridines, and particularly 1'-NH-alkyl derivatives, show promising in vitro activity against chloroquine-resistant P. falciparum isolates (6) . Here we report the results for a wider series of 9-anilinoacridines; we studied structureactivity relationships for both in vitro antimalarial activity and mammalian cell toxicity. A comparison of the structureactivity relationships among the various substituted 9-anilinoacridines indicated modifications which substantially increase the in vitro activity against P. falciparum. To evaluate the effects of the same 9-anilinoacridines on mammalian cells, the 50% inhibitory concentrations (IC.,s) of the compounds against a mammalian (leukemia) cell line were determined. Many 9-anilinoacridines (e.g., amsacrine) are potent inhibitors of mammalian DNA topoisomerase II (13) , and we have confirmed that the 9-anilinoacridine derivative most active against P. falciparum inhibits the type II topoisomerase in partially purified preparations from P. falciparum. Pyronaridine, a 9-anilino-aza-acridine which is showing promise in clinical trials against drug-resistant human malaria in the People's Republic of China (4, 8) , also inhibited P. falciparum topoisomerase II.
These results and those of previous studies (7) showing that 9-anilinoacridines can be modified to selectively target topoisomerase II in drug-resistant mammalian cells suggest that tailoring such compounds to specifically inhibit the malarial parasite topoisomerase II may be a feasible approach for treating drug-resistant malaria. * Corresponding author.
MATERIALS AND METHODS
The new 9-anilinoacridines described here were prepared by slight modifications of previously published methods (5) . Full details of the synthesis will be published elsewhere. Pyronaridine was obtained from the Walter Reed Army Hospital, Washington, D.C. Kinetoplast DNA was purchased from Topogen.
Drug lipophilicity was measured by thin-layer chromatography on a cellulose support at a pH of ca. 2 as reported previously (3) . The relative mobility (Rm) [log (1IRf -1)]) values of many 9-anilinoacridines determined in this way have correlated well with log P (n-octanol-water partition coefficient) values (2) . However, the method does have drawbacks with polybasic compounds of the type considered here, since relationships between the charge state of the compounds in the chromatography buffer and under physiological conditions are not clear. Ionization constant (pKa) values for both the acridine ring and (where applicable) the side chains were obtained from the literature where possible and were estimated by using data for related compounds when information in the literature was not available (5) . 
RESULTS
Previous studies (6) showed that 9-anilinoacridines bearing 1'-NH-alkyl substituents possess various levels of activity (0.4 to 2.6 ,uM) against chloroquine-and pyrimethamineresistant P. falciparum. We have extended the range of 1' substituents to include OH and CH2 (alkylamino) compounds (compounds 1 to 11 in Table 1 ). In addition, since earlier studies (6) showed that 3-amino substitution in the acridine ring leads to increased potency, a number of 3-NH2 and 3,6-diNH2 analogs of compounds with acceptable 1' substituents were also evaluated (compounds 12 to 19 in Table 1 ). Table 1 show that 1' substituents on 9-anilinoacridines have a moderate influence on in vitro antimalarial potency. One aim of the present study was to determine the influence of 1'-NH-R substituents, which are known to permit ready metabolic oxidation of 9-anilinoacridines to the corresponding diimines (10) . These then undergo rapid hydrolysis to the quinoneimines and 1,4-addition by nucleophiles to form 5' and 6' conjugates (10, 12) . However, the data show little difference in potency between compounds capable of metabolism by this route (compounds 1 to 4 and 7) and those which are not (compounds 5, 6 , and 8 to 11), suggesting that it is not a determinant of activity. In fact, the 1'-CH2-R analogs were consistently the most potent of the mono-substituted compounds.
Because of the increase in antimalarial potency by 3-NH2 acridine substitution shown earlier (6), a series of 3-NH2 and 3,6-diNH2 analogs of selected 1'-substituted compounds were also evaluated. The 3-NH2 compounds (compounds 12, 14, 16, and 18) were, on average, no more potent than the corresponding compounds (compounds 1, 2, 5, and 10) with an unsubstituted acridine, although there were individual differences (e.g., compounds 1 and 12). However, the 3,6-diNH2 compounds (compounds 13, 15, 17, and 19) were all significantly (ca. 10-fold) more potent against P. falciparum, with IC50s in the low nanomolar range, approaching that of the new antimalarial agent pyronaridine (compound 22) (IC50, 2.7 nM).
Some broad relationships between drug properties and in vitro antimalarial activity can be discerned. Compounds 1 to 11, with different C-i' substituents, have acridine pKa values ranging from 7.7 to 8.5, which are sufficiently high and similar to ensure reasonable ionization at physiological pH, and the DNA binding constants are sufficiently similar to suggest that these parameters do not strongly influence activity. In contrast, the two most lipophilic compounds (compounds 3 and 4) were least active against P. falciparum, suggesting that high lipophilicity is an undesirable feature and that high hydrophilicity is necessary to obtain highly active drugs. The data for the next two compounds (compounds 12 and 13) agree with these conclusions. The pKa values of these two compounds correlated with their activities and they are hydrophilic because of their complete ionization at physiological pH, with the most hydrophilic compound being the 3,6-diamino-1'-amino derivative (compound 13) with an IC50 of 25 nM. Overall, the most active compounds (IC50s, <0.3 p,M) are all relatively hydrophilic molecules with negative Rm values, and this appears to be the most important global parameter for good antimalarial activity. Although the antimalarial agent pyronaridine possesses a relatively weakly basic acridine-like chromophore, it is also very hydrophilic because of its 1-aza atom and doubly-basic side chain.
Structure-activity relationships for the mammalian cytotoxicities of the compounds (measured as IC50s against cultured Jurkat human leukemia cells) were quite different, with the 3,6-diNH2 compounds being considerably less cytotoxic than either the 3-NH2-substituted or unsubstituted analogs. Inhibition of Jurkat cell growth was usually accompanied by considerable enlargement of the cells, possibly indicating inhibition in the G2 phase of the cell cycle, as occurs with other known DNA topoisomerase inhibitors (15) .
The opposing effects of 3,6-diNH2 substitution (enhanced toxicity against P. falciparum but reduced mammalian cell cytotoxicity) are reflected in the large increase in the in vitro therapeutic index (IVTI; defined as IC50 for Jurkat cells/IC50 for P. falciparum) seen for the 3,6-diNH2 compounds. The IVTI of compound 13 (IVTI, 600), is superior to that of pyronaridine (compound 22) (IVTI, 550), and indicates that further exploration of this and related substitution patterns in 9-anilinoacridines is warranted.
The overall structure-activity relationships of the 9-anilinoacridines for inhibition of malarial parasites are likely to reflect effects on drug penetration as well as DNA topo- isomerase II inhibition. While both compound 13 and pyronaridine (compound 22) inhibit P. falciparum DNA topoisomerase II in vitro, structure-activity relationships for activity against topoisomerase II have not yet been determined for all of the compounds. However, with the availability of an in vitro assay for the topoisomerase II from P. falciparum, it should now be possible to identify any structural features of the drugs that enhance inhibition of the enzyme. Previous studies (7) have shown that it is possible to develop 9-anilinoacridine variants with selective activity against isozymes of mammalian DNA topoisomerase II, and it is expected that the P. falciparum topoisomerase II should be at least as distinct as these isozymes. Interestingly, the concentrations of both compound 13 and pyronaridine required to inhibit the decatenation of P. falciparum DNA topoisomerase II were higher than those observed to inhibit whole-cell growth. However, other studies (16) parasite (1, 9) . These observations are a useful starting point from which to develop even more effective drugs of this series.
